Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclopentanone ring-cleaved pleuromutilin derivatives.

Dane M Springer1, Amy Bunker, Bing-Yu Luh

  • 1Anti-infective Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, P.O. Box 5100, Wallingford, CT 06492, USA. springd@wyeth.com <springd@wyeth.com>

European Journal of Medicinal Chemistry
|December 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimization of Covalent Warhead Trajectory for KRAS<sup>G12C</sup> Active-State Inhibition.

Journal of medicinal chemistry·2026
Same author

Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS<sup>G12C</sup> Active-State Inhibition.

Journal of medicinal chemistry·2026
Same author

Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C.

Nature communications·2026
Same author

Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation Pathway.

Journal of medicinal chemistry·2025
Same author

Empowering Voices: Inspiring Women in Medicinal Chemistry.

ACS medicinal chemistry letters·2024
Same author

Empowering Voices: Inspiring Women in Medicinal Chemistry.

Journal of medicinal chemistry·2024

New pleuromutilin derivatives with a [5.3.1] bicyclic core show antibacterial promise. Four compounds demonstrated potent activity against Streptococcus pneumoniae and Staphylococcus aureus in vitro.

Area of Science:

  • Medicinal Chemistry
  • Microbiology
  • Organic Synthesis

Background:

  • Pleuromutilin antibiotics are a class of naturally derived compounds with established antibacterial activity.
  • The emergence of antibiotic resistance necessitates the development of novel antibacterial agents.
  • Exploring novel chemical scaffolds is crucial for discovering new therapeutic options.

Purpose of the Study:

  • To synthesize and characterize novel ring-cleaved pleuromutilin derivatives.
  • To evaluate the in vitro antibacterial efficacy of these novel compounds.
  • To identify lead compounds with potential for further development against key bacterial pathogens.

Main Methods:

  • Synthesis of pleuromutilin derivatives incorporating a [5.3.1] bicyclic core structure.

Related Experiment Videos

  • In vitro antibacterial assays were performed using standard microbiological techniques.
  • Minimum Inhibitory Concentrations (MICs) were determined against reference strains of Streptococcus pneumoniae and Staphylococcus aureus.

    • Main Results:

    • A series of novel ring-cleaved pleuromutilin derivatives were successfully synthesized.
    • Four of the synthesized compounds exhibited significant in vitro antibacterial activity.
    • These compounds demonstrated Minimum Inhibitory Concentrations (MICs) less than or equal to 4 microg/mL against Streptococcus pneumoniae and Staphylococcus aureus.

    Conclusions:

    • The novel [5.3.1] bicyclic pleuromutilin derivatives represent a promising new class of antibacterial agents.
    • The identified compounds warrant further investigation for their potential therapeutic applications.
    • This study highlights the potential of scaffold modification in pleuromutilin antibiotic discovery.